Scholarlink

Aims <p>We investigated factors associated with early and long-term changes in renal function after initiating dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with moderate-to-advanced chronic kidney disease (CKD).</p> Methods <p>A total of 124 patients (mean age, 70.0 ± 13.1&#xa0;years; 93 men and 31 women) were retrospectively evaluated after 12&#xa0;months of 10 mg dapagliflozin treatment based on changes in estimated glomerular filtration rate (eGFR). All patients had moderate-to-advanced CKD (mean eGFR: 36.8 ± 11.4&#xa0;mL/min/1.73 m<sup>2</sup>; stage G3, n = 86; G4, n = 36; G5, n = 2). We used a multiple linear regression analysis to determine the independent factors associated with changes in eGFR during the administration of 12 months and first 1 month following dapagliflozin treatment.</p> Results <p>Systolic blood pressure (SBP) (standard coefficient (β) =  − 0.499, probability (p) = 0.002) was independently correlated with change in eGFR during the administration of dapagliflozin. SBP (β =  − 0.265, p = 0.040), change in eGFR during the 12 months before dapagliflozin administration (β =  − 0.453, p &lt; 0.001), and urinary protein-to-creatinine ratio (β =  − 0.282, p = 0.028) were independently correlated with the change in eGFR during the first 1 month of dapagliflozin administration.</p> Conclusions <p>SBP was associated with long-term change in eGFR after initiating dapagliflozin treatment in moderate-to-advanced CKD patients; SBP, urinary protein-to-creatinine ratio, and eGFR change before dapagliflozin administration were associated with early change in eGFR following dapagliflozin treatment in these patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systolic blood pressure is associated with early and long-term changes in renal function in patients with dapagliflozin-treated moderate-to-advanced chronic kidney disease

  • 期刊论文

  • 发表日期：

    2025年4月16日

查看全文
  • Katsunori Yanai,
  • Keiji Hirai,
  • Taisuke Kitano,
  • Haruhisa Miyazawa,
  • Kiyonori Ito,
  • Susumu Ookawara,
  • Yoshiyuki Morishita

摘要

Aims

We investigated factors associated with early and long-term changes in renal function after initiating dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with moderate-to-advanced chronic kidney disease (CKD).

Methods

A total of 124 patients (mean age, 70.0 ± 13.1 years; 93 men and 31 women) were retrospectively evaluated after 12 months of 10 mg dapagliflozin treatment based on changes in estimated glomerular filtration rate (eGFR). All patients had moderate-to-advanced CKD (mean eGFR: 36.8 ± 11.4 mL/min/1.73 m2; stage G3, n = 86; G4, n = 36; G5, n = 2). We used a multiple linear regression analysis to determine the independent factors associated with changes in eGFR during the administration of 12 months and first 1 month following dapagliflozin treatment.

Results

Systolic blood pressure (SBP) (standard coefficient (β) =  − 0.499, probability (p) = 0.002) was independently correlated with change in eGFR during the administration of dapagliflozin. SBP (β =  − 0.265, p = 0.040), change in eGFR during the 12 months before dapagliflozin administration (β =  − 0.453, p < 0.001), and urinary protein-to-creatinine ratio (β =  − 0.282, p = 0.028) were independently correlated with the change in eGFR during the first 1 month of dapagliflozin administration.

Conclusions

SBP was associated with long-term change in eGFR after initiating dapagliflozin treatment in moderate-to-advanced CKD patients; SBP, urinary protein-to-creatinine ratio, and eGFR change before dapagliflozin administration were associated with early change in eGFR following dapagliflozin treatment in these patients.